Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Sell
42
PETS Quote, Financials, Valuation and Earnings
Last price:
$3.29
Seasonality move
:
5.08%
Day range:
$3.26 - $3.35
52-week range:
$1.57 - $5.58
Dividend yield:
0%
P/E ratio:
337.00x
P/S ratio:
0.35x
P/B ratio:
1.65x
Volume:
287.1K
Avg. volume:
5.2M
1-year change:
-30.54%
Market cap:
$70.9M
Revenue:
$227M
EPS (TTM):
-$2.65
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PETS
PetMed Express, Inc.
|
$69.3M | -- | 2% | -- | $2.75 |
|
CDT
CDT Equity, Inc.
|
-- | -- | -- | -- | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$3.5M | -$0.90 | -7.14% | -69.46% | $52.67 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
$428.6K | -$0.78 | -100% | -4.46% | $47.33 |
|
ORKA
Oruka Therapeutics, Inc.
|
-- | -$0.62 | -- | -23.21% | $52.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PETS
PetMed Express, Inc.
|
$3.32 | $2.75 | $70.9M | 337.00x | $0.30 | 0% | 0.35x |
|
CDT
CDT Equity, Inc.
|
$1.51 | -- | $2.5M | -- | $0.00 | 0% | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$14.87 | $52.67 | $465.3M | -- | $1.03 | 0% | 23.72x |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MAZE
Maze Therapeutics, Inc.
|
$40.32 | $47.33 | $1.9B | -- | $0.00 | 0% | 501.13x |
|
ORKA
Oruka Therapeutics, Inc.
|
$27.86 | $52.17 | $1.3B | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PETS
PetMed Express, Inc.
|
1.75% | -0.144 | 1.46% | 0.67x |
|
CDT
CDT Equity, Inc.
|
30.47% | -0.944 | 27% | 1.13x |
|
LENZ
LENZ Therapeutics, Inc.
|
0.49% | -0.162 | 0.07% | 12.39x |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
5.99% | 0.000 | 1.94% | 17.36x |
|
ORKA
Oruka Therapeutics, Inc.
|
0.39% | 1.530 | 0.2% | 16.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PETS
PetMed Express, Inc.
|
$10.1M | -$8.4M | -72.91% | -73.88% | -18.89% | -$4.8M |
|
CDT
CDT Equity, Inc.
|
-$885K | -$7M | -898.82% | -- | -- | -$4.4M |
|
LENZ
LENZ Therapeutics, Inc.
|
$12.4M | -$18.9M | -28.93% | -29.1% | -151.1% | -$9M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
-$571K | -$33M | -30.65% | -35.16% | -- | -$24.7M |
|
ORKA
Oruka Therapeutics, Inc.
|
-$20K | -$34.1M | -25.67% | -25.76% | -- | -$21.7M |
PetMed Express, Inc. vs. Competitors
-
Which has Higher Returns PETS or CDT?
CDT Equity, Inc. has a net margin of -19.21% compared to PetMed Express, Inc.'s net margin of --. PetMed Express, Inc.'s return on equity of -73.88% beat CDT Equity, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PETSPetMed Express, Inc.22.85% -$0.41 $43.8M CDTCDT Equity, Inc.-- -$13.16 $6.2M -
What do Analysts Say About PETS or CDT?
PetMed Express, Inc. has a consensus price target of $2.75, signalling downside risk potential of -17.17%. On the other hand CDT Equity, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that PetMed Express, Inc. has higher upside potential than CDT Equity, Inc., analysts believe PetMed Express, Inc. is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PETSPetMed Express, Inc.0 0 1 CDTCDT Equity, Inc.0 0 0 -
Is PETS or CDT More Risky?
PetMed Express, Inc. has a beta of 0.649, which suggesting that the stock is 35.118% less volatile than S&P 500. In comparison CDT Equity, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PETS or CDT?
PetMed Express, Inc. has a quarterly dividend of $0.30 per share corresponding to a yield of 0%. CDT Equity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PetMed Express, Inc. pays -166.63% of its earnings as a dividend. CDT Equity, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PETS or CDT?
PetMed Express, Inc. quarterly revenues are $44.4M, which are larger than CDT Equity, Inc. quarterly revenues of --. PetMed Express, Inc.'s net income of -$8.5M is lower than CDT Equity, Inc.'s net income of -$7.1M. Notably, PetMed Express, Inc.'s price-to-earnings ratio is 337.00x while CDT Equity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PetMed Express, Inc. is 0.35x versus -- for CDT Equity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PETSPetMed Express, Inc.0.35x 337.00x $44.4M -$8.5M CDTCDT Equity, Inc.-- -- -- -$7.1M
-
Which has Higher Returns PETS or LENZ?
LENZ Therapeutics, Inc. has a net margin of -19.21% compared to PetMed Express, Inc.'s net margin of -133.6%. PetMed Express, Inc.'s return on equity of -73.88% beat LENZ Therapeutics, Inc.'s return on equity of -29.1%.
Company Gross Margin Earnings Per Share Invested Capital PETSPetMed Express, Inc.22.85% -$0.41 $43.8M LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M -
What do Analysts Say About PETS or LENZ?
PetMed Express, Inc. has a consensus price target of $2.75, signalling downside risk potential of -17.17%. On the other hand LENZ Therapeutics, Inc. has an analysts' consensus of $52.67 which suggests that it could grow by 254.18%. Given that LENZ Therapeutics, Inc. has higher upside potential than PetMed Express, Inc., analysts believe LENZ Therapeutics, Inc. is more attractive than PetMed Express, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PETSPetMed Express, Inc.0 0 1 LENZLENZ Therapeutics, Inc.5 0 0 -
Is PETS or LENZ More Risky?
PetMed Express, Inc. has a beta of 0.649, which suggesting that the stock is 35.118% less volatile than S&P 500. In comparison LENZ Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PETS or LENZ?
PetMed Express, Inc. has a quarterly dividend of $0.30 per share corresponding to a yield of 0%. LENZ Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. PetMed Express, Inc. pays -166.63% of its earnings as a dividend. LENZ Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PETS or LENZ?
PetMed Express, Inc. quarterly revenues are $44.4M, which are larger than LENZ Therapeutics, Inc. quarterly revenues of $12.5M. PetMed Express, Inc.'s net income of -$8.5M is higher than LENZ Therapeutics, Inc.'s net income of -$16.7M. Notably, PetMed Express, Inc.'s price-to-earnings ratio is 337.00x while LENZ Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PetMed Express, Inc. is 0.35x versus 23.72x for LENZ Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PETSPetMed Express, Inc.0.35x 337.00x $44.4M -$8.5M LENZLENZ Therapeutics, Inc.23.72x -- $12.5M -$16.7M
-
Which has Higher Returns PETS or LIMN?
Liminatus Pharma has a net margin of -19.21% compared to PetMed Express, Inc.'s net margin of --. PetMed Express, Inc.'s return on equity of -73.88% beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PETSPetMed Express, Inc.22.85% -$0.41 $43.8M LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About PETS or LIMN?
PetMed Express, Inc. has a consensus price target of $2.75, signalling downside risk potential of -17.17%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that PetMed Express, Inc. has higher upside potential than Liminatus Pharma, analysts believe PetMed Express, Inc. is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings PETSPetMed Express, Inc.0 0 1 LIMNLiminatus Pharma0 0 0 -
Is PETS or LIMN More Risky?
PetMed Express, Inc. has a beta of 0.649, which suggesting that the stock is 35.118% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PETS or LIMN?
PetMed Express, Inc. has a quarterly dividend of $0.30 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PetMed Express, Inc. pays -166.63% of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PETS or LIMN?
PetMed Express, Inc. quarterly revenues are $44.4M, which are larger than Liminatus Pharma quarterly revenues of --. PetMed Express, Inc.'s net income of -$8.5M is higher than Liminatus Pharma's net income of --. Notably, PetMed Express, Inc.'s price-to-earnings ratio is 337.00x while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PetMed Express, Inc. is 0.35x versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PETSPetMed Express, Inc.0.35x 337.00x $44.4M -$8.5M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns PETS or MAZE?
Maze Therapeutics, Inc. has a net margin of -19.21% compared to PetMed Express, Inc.'s net margin of --. PetMed Express, Inc.'s return on equity of -73.88% beat Maze Therapeutics, Inc.'s return on equity of -35.16%.
Company Gross Margin Earnings Per Share Invested Capital PETSPetMed Express, Inc.22.85% -$0.41 $43.8M MAZEMaze Therapeutics, Inc.-- -$0.63 $403.6M -
What do Analysts Say About PETS or MAZE?
PetMed Express, Inc. has a consensus price target of $2.75, signalling downside risk potential of -17.17%. On the other hand Maze Therapeutics, Inc. has an analysts' consensus of $47.33 which suggests that it could grow by 17.39%. Given that Maze Therapeutics, Inc. has higher upside potential than PetMed Express, Inc., analysts believe Maze Therapeutics, Inc. is more attractive than PetMed Express, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PETSPetMed Express, Inc.0 0 1 MAZEMaze Therapeutics, Inc.9 0 0 -
Is PETS or MAZE More Risky?
PetMed Express, Inc. has a beta of 0.649, which suggesting that the stock is 35.118% less volatile than S&P 500. In comparison Maze Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PETS or MAZE?
PetMed Express, Inc. has a quarterly dividend of $0.30 per share corresponding to a yield of 0%. Maze Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PetMed Express, Inc. pays -166.63% of its earnings as a dividend. Maze Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PETS or MAZE?
PetMed Express, Inc. quarterly revenues are $44.4M, which are larger than Maze Therapeutics, Inc. quarterly revenues of --. PetMed Express, Inc.'s net income of -$8.5M is higher than Maze Therapeutics, Inc.'s net income of -$30.1M. Notably, PetMed Express, Inc.'s price-to-earnings ratio is 337.00x while Maze Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PetMed Express, Inc. is 0.35x versus 501.13x for Maze Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PETSPetMed Express, Inc.0.35x 337.00x $44.4M -$8.5M MAZEMaze Therapeutics, Inc.501.13x -- -- -$30.1M
-
Which has Higher Returns PETS or ORKA?
Oruka Therapeutics, Inc. has a net margin of -19.21% compared to PetMed Express, Inc.'s net margin of --. PetMed Express, Inc.'s return on equity of -73.88% beat Oruka Therapeutics, Inc.'s return on equity of -25.76%.
Company Gross Margin Earnings Per Share Invested Capital PETSPetMed Express, Inc.22.85% -$0.41 $43.8M ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M -
What do Analysts Say About PETS or ORKA?
PetMed Express, Inc. has a consensus price target of $2.75, signalling downside risk potential of -17.17%. On the other hand Oruka Therapeutics, Inc. has an analysts' consensus of $52.17 which suggests that it could grow by 87.25%. Given that Oruka Therapeutics, Inc. has higher upside potential than PetMed Express, Inc., analysts believe Oruka Therapeutics, Inc. is more attractive than PetMed Express, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PETSPetMed Express, Inc.0 0 1 ORKAOruka Therapeutics, Inc.11 0 0 -
Is PETS or ORKA More Risky?
PetMed Express, Inc. has a beta of 0.649, which suggesting that the stock is 35.118% less volatile than S&P 500. In comparison Oruka Therapeutics, Inc. has a beta of -0.394, suggesting its less volatile than the S&P 500 by 139.44%.
-
Which is a Better Dividend Stock PETS or ORKA?
PetMed Express, Inc. has a quarterly dividend of $0.30 per share corresponding to a yield of 0%. Oruka Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. PetMed Express, Inc. pays -166.63% of its earnings as a dividend. Oruka Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PETS or ORKA?
PetMed Express, Inc. quarterly revenues are $44.4M, which are larger than Oruka Therapeutics, Inc. quarterly revenues of --. PetMed Express, Inc.'s net income of -$8.5M is higher than Oruka Therapeutics, Inc.'s net income of -$30.3M. Notably, PetMed Express, Inc.'s price-to-earnings ratio is 337.00x while Oruka Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PetMed Express, Inc. is 0.35x versus -- for Oruka Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PETSPetMed Express, Inc.0.35x 337.00x $44.4M -$8.5M ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
